Online Trial Tracker - Larvol Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

busulfan / Generic mfg.

NCT00003081: Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma

Completed

filgrastim, busulfan, melphalan, thiotepa, peripheral blood stem cell transplantation, radiation therapy

Fred Hutchinson Cancer Center, National Cancer Institute (NCI)

Sarcoma

01/02

NCT00003926: Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated

amifostine trihydrate, Ethyol, busulfan, Busulfex, filgrastim, granulocyte colony-stimulating factor, G-CSF, melphalan, Alkeran, thiotepa, Thioplex, peripheral blood stem cell transplantation (PBSC), bone marrow transplant

Masonic Cancer Center, University of Minnesota

Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma

08/02

08/03

NCT00006246: Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

Completed

busulfan

Pediatric Brain Tumor Consortium, National Cancer Institute (NCI)

Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma

05/03

NCT00112645: Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors

Completed

anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation

Milton S. Hershey Medical Center

Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific

04/10

02/11

NCT00623077: MT2004-30: Tomotherapy for Solid Tumors

Terminated

filgrastim, G-CSF, Sargramostim, busulfan, Busulfex, Myleran, etoposide, Eposin, VP-16, ifosfamide, Mitoxana, Ifex, melphalan, Alkeran, thiotepa, stem cell transplantation, HPC infusion, tomotherapy, total marrow irradiation, Mesna, Uromitexan®, Mesnex, Whole lung radiation

Masonic Cancer Center, University of Minnesota

Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma, Sarcoma

07/12

10/16

NCT00638898: Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

Active, not recruiting

busulfan, BSF, BU, Misulfan, Mitosan, Myeloleukon, Myelosan, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, Melfalan, topotecan hydrochloride, hycamptamine, Hycamtin, SKF S-104864-A, TOPO, laboratory biomarker analysis, filgrastim, G-CSF, granulocyte colony-stimulating factor, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, autologous hematopoietic stem cell transplantation, pharmacological study, pharmacological studies, autologous bone marrow transplantation, ABMT, bone marrow transplantation, autologous, transplantation, autologous bone marrow

City of Hope Medical Center

Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific

01/13

12/24

NCT01969942: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

Withdrawn

allogeneic stem cell transplantation, Clyclophosphamide, Fludarabina, Busulfan, Melphalan

University of Louisville

Ewing Sarcoma

10/16

Ewing/Allo, NCT02472392: Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed

Rabbit anti-thymocyte globulin, ATG, thymoglobulin, Busulfan, Busulfex, Myleran, Melphalan, L-PAM, L-Sarcolysin, Phenylalanine Mustard, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Neosar

University of Louisville

EWINGS SARCOMA

12/16

NCT01625351: A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed

alemtuzumab, CAMPATH-1H, Campath(R), fludarabine, Fludara(R), sirolimus, Rapamycin, Rapamune(R), Busulfan, Busulfex(R), Myleran(R), melphalan, L-phenylalanine mustard, phenylalanine mustard, L-PAM, L-sarcolysin, stem cells, HSCT, Stem cell transplantation, CliniMACS, Cell Selection System

St. Jude Children's Research Hospital, CURE Childhood Cancer, Inc.

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma

02/20

NYESO SCT, NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated

18F-FHBG, Reporter Probe 18F-FHBG, Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cellular Therapy, Cell Therapy, Computed Tomography, CAT, CAT Scan, Computerized Axial Tomography, Computerized Tomography, CT, CT SCAN, tomography, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Granix, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine, Fluradosa, Leukapheresis, Leukocytopheresis, Therapeutic Leukopheresis, Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging

Jonsson Comprehensive Cancer Center, California Institute for Regenerative Medicine (CIRM)

HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma

10/23



	Diseases Companies Products Productz Mechanisms of Action Sites